Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer With Low to Intermediate HER2 Expression
Interventions: BIOLOGICAL: NeuVax™ vaccine|BIOLOGICAL: Leukine® (sargramostim, GM-CSF) and water for injection
Sponsor: Galena Biopharma, Inc.